---
title: "Biodexa Announces Exclusive License Of Otsuka’S Opb-171775, A Potent Phase 1 Ready Molecular Glue For Gist"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/274823199.md"
datetime: "2026-02-04T13:42:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/274823199.md)
  - [en](https://longbridge.com/en/news/274823199.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/274823199.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/274823199.md) | [繁體中文](https://longbridge.com/zh-HK/news/274823199.md)


# Biodexa Announces Exclusive License Of Otsuka’S Opb-171775, A Potent Phase 1 Ready Molecular Glue For Gist

Feb 4 (Reuters) - Biodexa Pharmaceuticals PLC (5MPy.F) : \* BIODEXA ANNOUNCES EXCLUSIVE LICENSE OF OTSUKA’S OPB-171775, A POTENT PHASE 1 READY MOLECULAR GLUE FOR GIST Source text: Further company coverage: (5MPy.F)

### Related Stocks

- [Otsuka Holdings Co., Ltd. (OTSKY.US)](https://longbridge.com/en/quote/OTSKY.US.md)
- [Biodesix, Inc. (BDSX.US)](https://longbridge.com/en/quote/BDSX.US.md)
- [State Street® SPDR® S&P® Biotech ETF (XBI.US)](https://longbridge.com/en/quote/XBI.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/en/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech ETF (FBT.US)](https://longbridge.com/en/quote/FBT.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/en/quote/BBH.US.md)
- [ProShares Ultra Nasdaq Biotechnology (BIB.US)](https://longbridge.com/en/quote/BIB.US.md)
- [Biodexa Pharmaceuticals Plc (BDRX.US)](https://longbridge.com/en/quote/BDRX.US.md)

## Related News & Research

- [bioAffinity Launches Major Lung Cancer Detection Study](https://longbridge.com/en/news/278565253.md)
- [UCB reports superiority of bimekizumab in psoriatic arthritis study](https://longbridge.com/en/news/278691960.md)
- [Otsuka (OTCMKTS:OTSKY) Updates FY 2026 Earnings Guidance](https://longbridge.com/en/news/276183996.md)
- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/en/news/278530484.md)
- [Pulse Biosciences Enrolls First Patient In NPulse Technology Study For Thyroid Microcarcinoma](https://longbridge.com/en/news/279027126.md)